Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Emory University (Winship Cancer Institute)

Sites in Atlanta, GA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 12:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1465
Shown on this page
12
Current sort
Recently updated
Campus scope
Emory University (Winship Cancer Institute), Atlanta, GA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Emory University (Winship Cancer Institute), Atlanta, GA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 121–132 of 1,465 matching trials with a site at Emory University (Winship Cancer Institute), Atlanta, GA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 3 Interventional

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

NCT06127407
Status at this site: Recruiting
View directory record Official record
Conditions
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Interventions
Ivosidenib 500mg, Placebo
Drug
Lead sponsor
Servier Bio-Innovation LLC
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
22
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 12:02 PM EDT
Recruiting Early Phase 1 Interventional

Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases

NCT06328686
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm
Interventions
Arginine, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Spectroscopy, Whole-Brain Radiotherapy
Drug · Procedure · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 12:02 PM EDT
Recruiting Phase 3 Interventional

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

NCT06274801
Status at this site: Recruiting
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Seralutinib, Gereic Dry Powder Inhaler
Drug · Device
Lead sponsor
Gossamer Bio USA, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
33
States / cities
Fresno, California • Los Angeles, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 12:02 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

NCT07412470
Status at this site: Recruiting
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Frexalimab, Tacrolimus, rabbit anti-thymocyte globulin, mycophenolate mofetil, mycophenolate sodium, methylprednisolone, prednisone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
14
States / cities
San Francisco, California • Atlanta, Georgia • Hines, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 12:02 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older

NCT07282665
Status at this site: Recruiting
View directory record Official record
Conditions
Clostridoides Difficile Associated Disease
Interventions
C.difficile vaccine, Saline Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
32,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
142
States / cities
Athens, Alabama • Guntersville, Alabama • Huntsville, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 12:02 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

NCT05206773
Site status not listed — check the official record
View directory record Official record
Conditions
Fabry Disease
Interventions
Venglustat (GZ402671), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
16 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 12:02 PM EDT
Recruiting Phase 3 Interventional

PREcision MEDicine In Achalasia (PREMEDIA)

NCT07293650
Status at this site: Recruiting
View directory record Official record
Conditions
Type I Achalasia, Type II Achalasia, EGJ Outflow Obstruction Without Spastic/Hypercontractile Features
Interventions
Standard Myotomy, Tailored Short Myotomy
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
16
States / cities
Scottsdale, Arizona • La Jolla, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 12:02 PM EDT
Active, not recruiting Not applicable Interventional

SpaceIT Hydrogel System for Perirectal Spacing

NCT06451614
Site status not listed — check the official record
View directory record Official record
Conditions
Prostate Cancer
Interventions
SpaceIT Hydrogel System, Commercially available Boston Scientific Spacer
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older · Male only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Laguna Hills, California • Los Angeles, California • Miami, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 12:02 PM EDT
Recruiting Phase 3 Interventional

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

NCT07544654
Status at this site: Recruiting
View directory record Official record
Conditions
Extrapulmonary Neuroendocrine Cancer (epNEC)
Interventions
Obrixtamig, Carboplatin, Etoposide, Ventana DLL3 RxDx assay
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 12:02 PM EDT
Recruiting Phase 2Phase 3 Interventional

Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

NCT05416307
Status at this site: Recruiting
View directory record Official record
Conditions
Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Interventions
ELA026
Drug
Lead sponsor
Electra Therapeutics Inc.
Industry
Eligibility
6 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 12:02 PM EDT
Recruiting Phase 1 Interventional

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

NCT07094204
Status at this site: Recruiting
View directory record Official record
Conditions
Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Interventions
ASP5834, panitumumab
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Santa Monica, California • Atlanta, Georgia • Jefferson, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 12:02 PM EDT
Active, not recruiting Phase 3 Interventional

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

NCT05047172
Site status not listed — check the official record
View directory record Official record
Conditions
Intracranial Arteriosclerosis, Stroke
Interventions
Ticagrelor + Aspirin, Rivaroxaban + Aspirin, Clopidogrel + Aspirin, Risk Factor Management
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
30 Years and older
Enrollment
1,683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
114
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 12:02 PM EDT

About this Emory University (Winship Cancer Institute) institution page

What this page lists
ClinicalTrials.gov records that list Emory University (Winship Cancer Institute) in Atlanta, GA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.